Skip to Content
Merck
All Photos(1)

Documents

MABC985

Sigma-Aldrich

Anti-TRAF4 Antibody, clone 5MLN-2H1

ascites fluid, clone 5MLN-2H1, from mouse

Synonym(s):

TNF receptor-associated factor 4, Cysteine-rich domain associated with RING and Traf domains protein 1, Metastatic lymph node gene 62 protein, MLN 62, RING finger protein 83

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

ascites fluid

antibody product type

primary antibodies

clone

5MLN-2H1, monoclonal

species reactivity

mouse, human

species reactivity (predicted by homology)

rat (based on 100% sequence homology)

technique(s)

immunocytochemistry: suitable
immunohistochemistry: suitable
western blot: suitable

isotype

IgG1

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... TRAF4(9618)

General description

TNF receptor-associated factor 4 (TRAF4), also known as Cysteine-rich domain associated with RING and Traf domains protein 1 (CART1), Metastatic lymph node gene 62 protein (MLN 62), and RING finger protein 83 (RNF83), is an adapter protein and signal transducer that links members of the TNF family to different signaling pathways. As such TRAF4 plays a role in the activation of the NF-kappa- and JNK signaling as well as a player in apoptosis and cell survival pathways. In development, TRAF4 is necessary for proper skeleton development and lung development. TRAF4 is localized in the perinuclear region of the cell as well as other locations including cell junctions where it is associated with various cytoskeletal elements. TRAF4 is expressed in the epithelial cells of thymus, respiratory tract, salivary gland, and esophagus. TRAF4 expression is regulated via the ubiquitin proteasome system and is a polyubiquitin target protein.

Specificity

This antibody detects TRAF4 and is cited in publications as both clone 5MLN-2H1 and clone 2H1.

Immunogen

Linear peptide corresponding to Human TRAF4.

Application

Imunnohistochemistry Analysis: A representative lot of this antibody detected TRAF4 in multiple human cancer tissues (Camilleri-Broet. S., et al. (2007) Oncogene. 26:142-147).

Imunnohistochemistry Analysis: A representative lot of this antibody detected TRAF4 in Breast cancer tissue (Kedinger, V., et. al. (2008) PLoS ONE. 3(10):e3518).

Immunocytochemistry Analysis: A representative lot of this antibody detected TRAF4 in MCF-10A cells and tranfected HeLa cells (Kedinger, V., et. al. (2008) PLoS ONE. 3(10):e3518).
Research Category
Apoptosis & Cancer
Research Sub Category
Tumor Markers
This Anti-TRAF4 Antibody, clone 5MLN-2H1 is validated for use in Western Blotting and Immunohistochemistry and Immunocytochemistry for the detection of TRAF4.

Quality

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:1000 dilution of this antibody detected TRAF4 in 10 µg of HeLa cell lysate.

Target description

~53 kDa observed

Physical form

Mouse monoclonal IgG1 ascites without preservatives.
Unpurified

Storage and Stability

Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Other Notes

Concentration: Please refer to lot specific datasheet.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jinzhuang Liao et al.
International journal of biological sciences, 20(1), 182-199 (2024-01-02)
Nasopharyngeal carcinoma (NPC) is the most common cancer originating in the nasopharynx. Despite continuous improvement in treatment strategies, recurrence or persistence of cancer after radiotherapy is still inevitable, highlighting the need to identify therapeutic resistance factors and develop effective methods
Ming Li et al.
Cell death & disease, 13(12), 1053-1053 (2022-12-20)
The E3 ligase TNF receptor-associated factor 4 (TRAF4) is frequently overexpressed and closely related to poor prognosis in human malignancies. However, its effect on carcinogenesis and radiosensitivity in oral squamous cell carcinoma (OSCC) remains unclear. The present study found that
Xin Dong et al.
Cell death & disease, 14(2), 102-102 (2023-02-11)
The E3 ligase TNF receptor-associated factor 4 (TRAF4) is upregulated and closely associated with tumorigenesis and the progression of multiple human malignancies. However, its effect on radiosensitivity in colorectal cancer (CRC) has not been elucidated. The present study found that
Yunxiao Liu et al.
International journal of oncology, 53(4), 1752-1762 (2018-07-18)
Circular RNAs (circRNAs), a class of endogenous RNAs, have emerged as an enigmatic class of genes. However, little is known about their value in the progression and chemoresistance of cancers. The present study sought to determine the expression profiles and
Xinfang Yu et al.
Journal of hematology & oncology, 13(1), 40-40 (2020-05-03)
Aberrant activation of DNA damage response (DDR) is a major cause of chemoresistance in colorectal cancer (CRC). CHK1 is upregulated in CRC and contributes to therapeutic resistance. We investigated the upstream signaling pathways governing CHK1 activation in CRC. We identified

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service